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RASSF2, a member of the RASSF1 family, has recently been identified as a potential tumour suppressor. We examined methylation
status in multiple regions which included the CpG island and spanned the transcription start site of RASSF2 in 10 gastric cancer cell
lines, as well as 78 primary gastric cancers and corresponding non-neoplastic gastric epithelia. Hypermethylation of RASSF2 in at least
one of the regions examined was detected in seven (70%) of the 10 cell lines; two (20%) exhibited hypermethylation in all the
regions examined including the transcription start site and lost expression of RASSF2 mRNA, which could, however, be restored by 5-
aza-20 deoxycytidine treatment, while the other five (50%) cell lines exhibited hypermethylation at the 50- and/or 30- edge, with four
of them expressing RASSF2 mRNA. In primary gastric cancers and corresponding non-neoplastic gastric epithelia, frequencies of
RASSF2 methylation ranged from 29% (23 out of 78) to 79% (62 out of 78) and 3% (two out of 78) to 60% (47 out of 78),
respectively, at different CpG sites examined. Methylation was frequently observed at the 50- and 30- edges, and became less frequent
near the transcription start site in both the primary gastric cancers and corresponding non-neoplastic gastric epithelia.
Hypermethylation near the transcription start site was mostly cancer-specific. We thus showed that RASSF2 is silenced by
hypermethylation near the transcription start site in gastric cancer. Hypermethylation was found initially to occur at the 50- and 30-
furthest regions of the CpG island in non-neoplastic gastric epithelia, to gradually spreads near the transcription start site to shut
down RASSF2 expression, and ultimately to constitute a field-defect placing tissue increased risk for development of gastric cancer.
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Human cancers develop and progress by accumulation of both
genetic and epigenetic alterations. Mutations of p53 are frequent
genetic (structural) alterations in gastric cancer (Tamura, 2002). E-
cadherin is inactivated through any combinations of gene
mutation, loss of heterozygosity (LOH), and promoter hyper-
methylation in gastric cancer, especially that of undifferentiated
histological type (Tamura et al, 2001). Recent evidences of
frequent silencing of hMLH1, p16, RUNX3, and other tumour
suppressor and tumour-related genes by promoter hypermethyla-
tion suggests that epigenetic alterations play the most important
role in gastric carcinogenesis (Tamura, 2004). Furthermore,
promoter hypermethylation initially occurs in non-neoplastic
gastric epithelia, increases with age, and ultimately silences gene
function to constitute a field-defect that may predispose tissues to
development of gastric cancer (Waki et al, 2002, 2003b). Many
genes become methylated in gastric epithelia during aging (Waki
et al, 2003a), although frequencies of methylation depends on the
sites of CpGs examined within a gene promoter (Satoh et al, 2002).
Ras family genes are associated with the signal transduction from
G-protein-coupled receptors and activation of the ras-signal
transduction pathway frequently observed in human tumours (Shih
et al, 1982; Malumbres and Pellicer, 1998; Ayllon and Rebollo, 2000).
Ras proteins interact with a wide spectrum of regulators and
downstream effectors to produce various cellular responses,
including cell proliferation, differentiation, and apoptosis (Mal-
umbres and Pellicer, 1998). Recently, the ras effectors/tumour
suppressors RASSF1 and NORE1 were found to be inactivated by
promoter hypermethylation in a variety of human tumours (Vavvas
et al, 1998; Dammann et al, 2000; Pfeifer et al, 2002; Hesson et al,
2003; Vos et al,2 0 0 3 b ) .RASSF2 was identified as a third member of
the RASSF1 family and a ras effector/tumour suppressor (Vos et al,
2003a). RASSF2 binds to K-ras in a GPT-dependent manner via the
Ras effector domain, but interacts with H-ras weakly (Vos et al,
2003a). RASSF2 inhibits the growth of tumour cells, promotes both
cell cycle arrest and apoptosis, and is frequently downregulated in
lung tumour cell lines (Vos et al, 2003a). The RASSF2-methylated
RKO, colorectal cell line, without RASSF2 RNA expression showed
increase of apoptosis and cell growth inhibition (Akino et al, 2005).
These observations indicate that RASSF2 shows tumour suppressor
activity in various human cancers.
In the present study, we examined the methylation status of
RASSF2 at multiple regions which included the CpG island and
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sspanned the transcription start site in gastric cancer cell lines, as
well as primary gastric cancers and corresponding non-neoplastic
gastric epithelia. The regions critical for methylation silencing of
RASSF2 mRNA expression were examined by analyses of cell lines,
while methylation spreading near the RASSF2 transcription start
site was examined by analyses of primary gastric cancers and
corresponding non-neoplastic gastric epithelia.
MATERIALS AND METHODS
Samples
A total of 10 gastric cancer cell lines with various histologies were
cultured under appropriate conditions in our laboratory: MKN1,
an adenosquamous cell carcinoma; MKN7, a well-differentiated
adenocarcinoma; MKN28 and MKN74, moderately differentiated
adenocarcinomas; MKN45 and KWS-I, poorly differentiated
adenocarcinomas; KATO-III, a signet ring cell carcinoma; ECC10
and ECC12, endocrine cell carcinomas; and TSG 11, a hepatoid
carcinoma. In total, 78 gastric cancer samples and matching non-
neoplastic gastric tissues were obtained at surgery from 78
patients. Clinicopathological data were available for 71 of the 78
patients (Table 1). The patients ranged in age from 43 to 89 years
(mean, 67.6 years). All the patients received follow-up care, for a
median of 36.1 months (range, 1–77 months.). All samples were
stored at  801C until processed. DNA was extracted from the 10
gastric cancer cell lines, 78 primary gastric cancers and
corresponding non-neoplastic gastric epithelia using SepaGene
(Sankyo-Junyaku, Tokyo, Japan). Total RNA was isolated from the
10 gastric caner cell lines with the TRIZOL reagent (Gibco BRL,
Life Technologies, Gaithersburg, MD, USA).
Methylation-specific PCR (MSP)
Treatment of DNA samples with sodium bisulphite converts all
unmethylated cytosines to uracils but does not affect methylated
cytosines. Briefly, 2mg of genomic DNA was denatured by
treatment with NaOH and modified by sodium bisulphite. The
samples were then purified using Wizard DNA purification resin
(Promega, Madison, WI, USA), treated with NaOH, recovered in
ethanol and resuspended in 30ml of distilled water. Amplification
was performed in a 20ml reaction volume containing 2mlo f
GeneAmp PCR Gold Buffer (PE Applied Biosystems, Foster City,
CA, USA), 1.0mM MgCl2,1ml of each primer, 0.2mM dNTPs, and
1U of Taq polymerase (AmpliTaq Gold DNA Polymerase, PE
Applied Biosystems). Hot start PCR was performed in a thermal
cycler (GeneAmp 2400, PE Applied Biosystems) for 35 cycles, each
of which consisted of denaturation at 951C for 15s, annealing at
551C for 15s, and extension at 721C for 30s, followed by a final 7-
min extension at 721C. A positive control and a negative control
(distilled water without DNA) were included for each amplifica-
tion. The PCR products were separated on a 6% nondenaturing
polyacrylamide gel. To detect regions playing critical roles in
regulating the expression of RASSF2A mRNA, we designed six
primer sets spanning the RASSF2 transcription start site and
including the CpG island (GenBank accession number AL 133354)
(Figure 1). The following primer sets were used: 50-GGT TTA AGT
TTT TCG GTT TAT TC-30 and 50-CAC GTC TAA CCG ACC CGC
CAA ATC G-30 for the methylated RASSF2-U2 sequence (upstream
2; the upstream sequence furthest from the transcription start site)
(212bp); 50-GGT TTA AGT TTT TTG GTT TAT TTG GA-30 and
50-TCA CAT CTA ACC AAC CCA CCA AAT CA-30 for the
unmethylated RASSF2-U2 sequence (213bp); 50-GTT TTT ATC
GGA TTT GTT CGT TC-30 and 50-CCA ACC CGA AAA AAT CGC
TAA CGA CG-30 for the methylated RASSF2-U1 sequence (up-
stream 1; the upstream sequence nearest the transcription start
site) (237bp); 50-GTT TTT ATT GGA TTT GTT TGT TTG-30 and
50-CCA ACC CAA AAA AAT CAC TAA CAA CA-30 for the
unmethylated RASSF2-U1 sequence (237bp); 50-GTA TTT CGC
GTT AGT GTT TC-30 and 50-TTA AAC CCG ACC CGC CGA TCG-
30 for the methylated RASSF2-D1 sequence (downstream 1; the
downstream sequence nearest the transcription start site in CpG
island) (183bp); 50-TTG GGT ATT TTG TGT TAG TGT TTT GTT-
30 and 50-ATT TAA ACC CAA CCC ACC AAT CAA T-30 for the
unmethylated RASSF2-D1 sequence (189bp); 50-CGG GTT TAA
AAA GAA GGA AGG AC-30 and 50-GCG CGA ACC CCC GCC AAA
AAC CG-30 for the methylated RASSF2-D2 sequence (135bp);
50-GTG GGT TTA AAA AGA AGG AAG GAT-30 and 50-CAC ACA
AAC CCC CAC CAA AAA CCA T-30 for the unmethylated RASSF2-
D2 sequence (137bp); 50-TTC GTT TAG AAG ACG GCG GC-30 and
50-CCT TCC TTC TTT TTA AAC CCG-30 for the methylated
Table 1 Correlation between RASSF2 CpG island hypermethylation and
clinicopathological characteristics in gastric cancer
RASSF2 methylation status
Characteristics Methylated at U1and D1 Others P-value
Number of patients 21 50
Age (mean) 69.4 66.9 NS
Gender NS
M1 5 3 6
F6 1 4
Stage NS
Early 7 8
Advanced 14 42
Histological differentiation NS
Differentiated 12 27
Undifferentiated 9 23
Location NS
Upper 4 9
Middle 6 18
Lower 10 19
Unknown 1 4
Lymph node metastasis NS
Present 11 31
Absent 10 19
Lymphatic permeation 0.033
ly ( )7 6
ly (+) 14 44
Venous permeation NS
v(  )8 1 0
v (+) 13 40
NS¼not significant by Fisher’s exact probability test and Mann–Whitney’s U-test.
CpG island
CpG
Location
TS B
3′ 5′
D1 D2 D3 D4 U2 U1 100 bp
Figure 1 Location of methylation-specific PCR (MSP) near the
transcription start site including (A) CpG island of RASSF2. Vertical lines
indicate individual CpG sites. TS, transcription start site; (B) exon 1 and
intron 1 boundary.
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TGG T-30 and 50-ATC CTT CCT TCT TTT TAA ACC CA-30 for the
unmethylated RASSF2-D3 sequence (170bp); 50-CGA AGG AGG
GCG GGG AGA TC-30 and 50-TCC GCC GCC GTC TTC TAA
ACG-30 for the methylated RASSF2-D4 sequence (downstream 4;
the downstream sequence of furthest from the transcription start
site) (148bp); and 50-GTT TTG AAG GAG GGT GGG GAG ATT-30
and 50-AAT CCA CCA CCA TCT TCT AAA CA-30 for the
unmethylated RASSF2-D4 sequence (154bp). The positions of
amplified regions are shown in Figure 1. As a positive control, Sss I
methylase (New England BioLabs, Inc., Beverly, MA, USA) was
used to methylate 100mg of liver tissue-derived DNA obtained
from an autopsy sample, and was modified by sodium bisulphite
as described above.
Reverse transcription–PCR (RT–PCR)
Isolated RNA was reverse-transcribed and amplified using a one-
step RT–PCR System (Gibco BRL). Primer sequences used were
50-AAG ACA TCC GTG TTC ACA CC-30 and 50-TCG TTC TCA
TGG CTC AGA TT-30 for RASSF2A mRNA (462bp); and sense,
50-AAA TCT GGC ACC ACA CCT T-30 and antisense, 50-AGC ACT
GTG TTG GCG TAC AG-30 for b-actin (646bp). Primers for
RASSF2A mRNA can also amplify RASSF2B mRNA product, but
product size of RASSF2B mRNA (409bp) is smaller than that of
RASSF2A mRNA. Thus, they could be differentiable.
5-aza-20-deoxycytidine (5-aza-dC) treatment
To examine restoration of RASSF2 mRNA expression, two cell
lines, KATO-III and KWS-I, were incubated for 96h with
5mM 5-aza-dC (Sigma, St Louis, MO, USA), and then harvested
for RNA extraction and RT–PCR. MKN74, which expresses
RASSF2 mRNA with an unmethylated CpG island, was used as
a control.
Statistical analysis
Statistical comparisons were performed using Fisher’s exact
probability test and Mann–Whitney’s U-test. Values of Po0.05
were considered significant.
RESULTS
Methylation status and mRNA expression of RASSF2 in
gastric cancer cell lines
Hypermethylation of RASSF2 in at least one of the regions
examined was detected in seven of the 10 cell lines, MKN1, MKN7,
MKN28, MKN45, KATO-III, KWS-I, and ECC10 (Figure 2A).
Among these, KATO-III and KWS-I exhibited hypermethylation in
all the regions examined, and lost RASSF2 mRNA expression
(Figure 2A), which, however, was restored by 5-aza-dC treatment
(Figure 2B). The other five of these seven cell lines, MKN1, MKN7,
MKN28, MKN45, and ECC10 exhibited methylation only in
outskirt regions, and four of them expressed RASSF2 mRNA
(Figure 2A). Three cell lines, MKN74, TSG11, and ECC12, did not
exhibit hypermethylation in any region. TSG11 and ECC12 lost
RASSF2 mRNA expression despite being unmethylated.
Hypermethylation RASSF2 CpG island in primary gastric
cancer and corresponding non-neoplastic gastric epithelia
Methylation frequencies of RASSF2 varied in the regions upstream
and downstream of the transcription start site. Of primary gastric
cancers and corresponding non-neoplastic epithelia, hypermethy-
lation was observed in 55% (43 out of 78) and 36% (28 out of 78) at
U2, 29% (23 out of 78) and 3% (two out of 78) at U1, 42% (33 out
of 78) and 6% (five out of 78) at D1, 45% (35 out of 78) and 13%
(10 out of 78) at D2, 54% (42 out of 78) and 28% (22 out of 78) at
D3, 79% (62 out of 78) and 60% (47 out of 78) at D4, respec-
tively (Figures 3 and 4). Unmethylated RASSF2 sequence was
present in all the samples (data not shown). Gastric cancers with
methylation at U1 and D1 exhibited significantly less frequent
lymphatic permeation than unmethylated gastric cancers (Table 1)
No significant correlation was observed between methylation
status of RASSF2 and other clinicopathological factors. Methyla-
tion status of RASSF2 did not significantly influence event-
free survival rate, as determined by Kaplan–Meier curve analysis
with the log-rank test and Breslow–Gehan–Wilcoxon test (data
not shown).
B
     SM –+–+++
KATO-III KWS-I MKN74
5-aza-dC
   -actin
RASSF 2
A
RT−PCR
123456789 1 0 M S
1 2 3 4 5 6 7 8 9 10 P DW SM
  -actin
RASSF 2
D1M
P DW SM
DW SM
D1U
U2M
U2U
U1M
U1U
P DW SM
DW SM
DW SM
P DW SM
D2M
DW SM
D2U
P DW SM
D3M
D3U
D4U
D4M
DW SM
P DW SM
DW SM
Figure 2 Reverse transcription–PCR and methylation-specific PCR
(MSP) (A), and comparison of RASSF2 mRNA expression before ( )
and after (þ) 5-aza-dC treatment (B) in gastric cancer cell lines. (A)
RASSF2 mRNA is present in lanes 1–3, 5, and 9. Methylated-PCR products
from U2M to D4M are present at all the regions in lanes 6 and 7, at only
the 50- and/or 30- edge in lanes 1–4, and 9, and not present in lanes 5, 8,
and 10. Unmethylated-PCR products from U2U to D4U are alternatively
present in lanes 1–5, and 8–10, and not present in lanes 6 and 7. Lanes 1,
MKN1; 2, MKN7; 3, MKKN28; 4, MKN45; 5, MKN74; 6, KATO-III; 7, KWS-I;
8, TSG11; 9, ECC10; 10, ECC12; P, positive control; DW, distilled water;
and SM, size marker. (B) Treatment with 5-aza-dC restored RASSF2 mRNA
expression in KATO-III and KWS-I, but did not affect levels of RASSF2
expression in MKN74.
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Results in gastric cancer cell lines suggest that hypermethylation
near the transcription start site was associated with loss of RASSF2
mRNA expression, although other mechanisms might also
contribute to RASSF2 silencing. While by analyses of samples
from primary gastric cancer patients, frequencies of methylation
at each region investigated were higher in primary gastric
cancers than in corresponding non-neoplastic gastric epithelia.
Very recently, Akino et al reported the significant association
between methylation and expression status of RASSF2 in colon
cancer cell lines and primary colorectal cancers. They identified
the RASSF2 promoter region and showed that absence of RASSF2
transcription was caused by DNA methylation, not by alteration
of transcription factors, and also showed histone acetylation
at the 50 region of RASSF2 in colorectal cancer cell lines with
DNA methylation (Akino et al, 2005). It has also been reported
that inactivation of RASSF2 with siRNA increased phospholila-
tion of MAP kinase, and that RASSF2 suppressed down-
stream signalling in the RAS pathway (Akino et al, 2005).
Colorectal tumours with RASSF2 methyaltion showed K-ras/BRAF
mutations significantly more frequently than those without
RASSF2 methyaltion (Akino et al, 2005), although earlier studies
have showed that K-ras mutation and RASSF2 methylation
are mutually exclusive (Hesson et al, 2005). In the present study,
we have showed that RASSF2 methylation is frequent in gastric
cancer, despite the rarity of K-ras/BRAF mutations in this tumour
(Kim IJ et al, 2003).
Methylation in the 50- and 30- furthest regions within the CpG
island was very frequent in both primary gastric cancers and
corresponding non-neoplastic gastric epithelia, but became less
frequent near the transcription start site. Methylation near the
transcription start sites at U1 and D1 appeared to be mostly
cancer-specific. These findings are essentially the same as those for
DAP-kinase hypermethylation (Satoh et al, 2002). Therefore, the
pattern of spread of methylation, initially at the outskirts of CpG
islands and then progressing to regions critical for gene silencing,
might be common to various types of methylation-related gene
silencing. Since frequencies of methylation are influenced by the
location of MSP, as noted above, the significance of detection of
DNA methylation in a giver tumour suppressor or tumour-related
gene varied significantly. For example, hypermethylation near the
transcription start site, which is cancer-specific and results in
gene silencing, can be used as a diagnostic marker of malignancy
in tissues or other samples, such as serum or ascites, and
hypermethylation at a region next to such a critical region might
be an early signal of carcinogenesis.
Gastric cancers with methylation at U1 and D1, a change critical
for RASSF2 silencing, exhibited significantly less frequent lym-
phatic permeation than unmethylated gastric cancers. Gastric
cancers with a high frequency of microsatellite instability (MSI-H),
which is the result of hMLH1 silencing by hypermethyla-
tion, exhibited less frequent lymph node metastasis (dos Santos
et al, 1996; Wu et al, 2000), and several genes are simultaneously
methylated together with hMLH1 (Kim H et al, 2003; Homma
et al, 2005).
In conclusion, hypermethylation of RASSF2 initially occurs in
the 50- and 30- outskirt regions of the CpG island in non-neoplastic
U2
U1
D1
D3
D2
D4
T  N  T  N  T     N  T N T     N   DW P SM
M146 M192 M218 M238 M271
Figure 3 Examples of methylation-specific PCR (MSP) in primary gastric
cancers (T) and corresponding non-neoplastic gastric epithelia (N).
Methylation is frequent in outskirt regions (U2 and D4), but becomes
less frequent near the transcription start site (U1 and D1) in both gastric
cancers and non-neoplastic gastric epithelia. DW, distilled water; P, positive
control; and SM, size marker.
Non-neoplastic gastric
epithelia (N =78)
Gastric cancer  (N =78)
80%
60%
40%
20%
0%
U2
Gastric cancer (N =78)
Non-neoplastic gastric epithelia (N =78)
U2
55 % (43)
36 % (28)
U1
29 % (23)
3 % (2)
D1
42 % (33)
6 % (5)
D2
45 % (35)
13 % (10)
D3
54 % (42)
28 % (22)
D4
79 % (62)
60 % (47)
D2 D3 D4
U1 D1
Figure 4 Percentages of hypermethylation in various regions (U2–D4) of RASSF2.
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down RASSF2 expression, and ultimately constitutes a field-defect
which places tissue at increased risk for the development of gastric
cancer.
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